Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Objective: An unmet need exists for a non-invasive biomarker assay to aid gastric cancer diagnosis. We aimed to develop a serum microRNA (miRNA) panel for identifying patients with all stages of gastric cancer from a high-risk population. Design: We conducted a three-phase, multicentre study comprising 5248 subjects from Singapore and Korea. Biomarker discovery and verification phases were done through comprehensive serum miRNA profiling and multivariant analysis of 578 miRNA candidates in retrospective cohorts of 682 subjects. A clinical assay was developed and validated in a prospective cohort of 4566 symptomatic subjects who underwent endoscopy. Assay performance was confirmed with histological diagnosis and compared with Helicobacter pylori (HP) serology, serum pepsinogens (PGs), ‘ABC’ method, carcinoembryonic antigen (CEA) and cancer antigen 19–9 (CA19-9). Cost-effectiveness was analysed using a Markov decision model. Results: We developed a clinical assay for detection of gastric cancer based on a 12-miRNA biomarker panel. The 12-miRNA panel had area under the curve (AUC)=0.93 (95% CI 0.90 to 0.95) and AUC=0.92 (95% CI 0.88 to 0.96) in the discovery and verification cohorts, respectively. In the prospective study, overall sensitivity was 87.0% (95% CI 79.4% to 92.5%) at specificity of 68.4% (95% CI 67.0% to 69.8%). AUC was 0.848 (95% CI 0.81 to 0.88), higher than HP serology (0.635), PG 1/2 ratio (0.641), PG index (0.576), ABC method (0.647), CEA (0.576) and CA19-9 (0.595). The number needed to screen is 489 annually. It is cost-effective for mass screening relative to current practice (incremental cost-effectiveness ratio=US$44 531/quality-of-life year). Conclusion: We developed and validated a serum 12-miRNA biomarker assay, which may be a cost-effective risk assessment for gastric cancer. Trial registration number: This study is registered with ClinicalTrials.gov (Registration number: NCT04329299).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · cited 1×
“18 The receiver operating characteristic curve was used to present the performance of individual miRNA or multivariant biomarker panels.”
MethodSiegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Bartel, D. P. (2018) · Cell · doi:10.1016/j.cell.2018.03.006 · Cited by 3,751
STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration
Cohen, J. F., Korevaar, D. A., Altman, D. G., Bruns, D. E., Gatsonis, C. A., Hooft, L., Irwig, L., Levine, D., Reitsma, J. B., de Vet, H. C. W., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-012799 · Cited by 2,570
Cited by
Exploring the potential of microRNA as a diagnostic tool for gestational diabetes
Elhag, D. A., & Al Khodor, S. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04269-2 · Cited by 20
Metadata
- Authors
- So, J. B. Y., Kapoor, R., Zhu, F., Koh, C., Zhou, L., Zou, R., Tang, Y. C., Goo, P. C. K., Rha, S. Y., Chung, H. C., Yoong, J., Yap, C. T., Rao, J., Chia, C.-K., Tsao, S., Shabbir, A., Lee, J., Lam, K.-P., Hartman, M., Yong, W. P., Too, H.-P., & Yeoh, K.-G.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2020-10-07
- Volume
- 70
- Issue
- 5
- Pages
- 829-837
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W3092368475
- Cited by
- 208
- References
- 4
- FWCI
- 6.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population. https://app.cochat.ai/papers/10.1136/gutjnl-2020-322065
- The paper
- So, J. B. Y., Kapoor, R., Zhu, F., Koh, C., Zhou, L., Zou, R., Tang, Y. C., Goo, P. C. K., Rha, S. Y., Chung, H. C., Yoong, J., Yap, C. T., Rao, J., Chia, C.-K., Tsao, S., Shabbir, A., Lee, J., Lam, K.-P., Hartman, M., . . . Yeoh, K.-G. (2021). Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population. Gut. https://doi.org/10.1136/gutjnl-2020-322065
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.